|
Market Closed -
Toronto S.E.
20:40:03 09/11/2026 GMT
|
5-day change | 1st Jan Change | ||
| 5.200 CAD | -6.64% |
|
+21.21% | -46.94% |
| 10-28 | BriaCell Therapeutics Corp. Reports Earnings Results for the Full Year Ended July 31, 2026 | CI |
| 10-27 | BriaCell Therapeutics Corp. Auditor Raises 'Going Concern' Doubt | CI |
Company Valuation: BriaCell Therapeutics Corp.
Data adjusted to current consolidation scope
| Fiscal Period: July | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Market Cap 1 | 78.61 | 101.5 | 106.4 | 13.63 | 12.81 | 29.89 |
| Change | - | 29.07% | 4.9% | -87.19% | -6.05% | 133.36% |
| Enterprise Value (EV) 1 | 21.37 | 60.42 | 85.18 | 12.77 | -5.058 | 9.35 |
| Change | - | 182.77% | 40.98% | -85.01% | -139.6% | 284.87% |
| P/E | -54.3x | -3.77x | -5.12x | -2.56x | -0.12x | -0.49x |
| PBR | 1.37x | 9.82x | -28.2x | -5.72x | 0.77x | 1.82x |
| PEG | - | -0x | 0.2x | 0x | -0x | 0x |
| Capitalization / Revenue | - | - | - | - | - | - |
| EV / Revenue | - | - | - | - | - | - |
| EV / EBITDA | -3.07x | -3.96x | -3.66x | -0.38x | 0.19x | -0.26x |
| EV / EBIT | -3.06x | -3.95x | -3.66x | -0.38x | 0.19x | -0.26x |
| EV / FCF | -3.65x | -8.81x | -5.37x | -1.18x | 0.27x | -0.57x |
| FCF Yield | -27.4% | -11.3% | -18.6% | -84.8% | 374% | -174% |
| Dividend per Share 2 | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - |
| EPS 2 | -14.22 | -259.8 | -195 | -43.68 | -62.19 | -6.97 |
| Distribution rate | - | - | - | - | - | - |
| Net sales | - | - | - | - | - | - |
| EBITDA 1 | -6.958 | -15.27 | -23.26 | -33.25 | -27.1 | -35.93 |
| EBIT 1 | -6.973 | -15.29 | -23.27 | -33.33 | -27.2 | -36.05 |
| Net income 1 | -0.4283 | -26.84 | -20.3 | -4.791 | -26.31 | -34.9 |
| Net Debt 1 | -57.24 | -41.04 | -21.25 | -0.8621 | -17.87 | -20.54 |
| Reference price 2 | 772.222 | 980.759 | 998.928 | 111.849 | 7.298 | 3.436 |
| Nbr of stocks (in thousands) | 102 | 103 | 107 | 122 | 1,755 | 8,700 |
| Announcement Date | 28/10/21 | 27/10/22 | 25/10/23 | 29/10/24 | 15/10/25 | 28/10/26 |
1USD in Million2USD
Estimates
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | 34.5M | |
| 17.43x | 6.68x | 12.81x | 1.71% | 66.7B | |
| 30.07x | 8.27x | 26.77x | 0.07% | 56.88B | |
| 38.45x | 6.84x | 20.45x | 0.85% | 56.53B | |
| 46.55x | 6.14x | 30.16x | -.--% | 46.49B | |
| 35.48x | 3.35x | 14.48x | -.--% | 44.8B | |
| -22.71x | 62.58x | -21.48x | -.--% | 41.59B | |
| 35.87x | 8.84x | 23.03x | 0.37% | 35.35B | |
| 41.46x | 8.08x | 26.8x | -.--% | 33.29B | |
| -69.81x | 13.21x | -71.01x | -.--% | 25.1B | |
| Average | 16.98x | 13.78x | 6.89x | 0.33% | 41B | |
| Weighted average by Cap. | 21.52x | 12.92x | 11.34x | 0.44% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- BCT Stock
- Valuation BriaCell Therapeutics Corp.
Select your edition
All financial news and data tailored to specific country editions
